Nav: Home

Precision-medicine platform for mild Alzheimer's disease and at-risk individuals

November 13, 2018

Alzheimer's disease (AD) is a progressive, neurodegenerative condition in which individuals exhibit memory loss, dementia, and impaired metabolism. Nearly all previous single-domain studies to treat AD have failed, likely because it is a complex disease with multiple underlying drivers contributing to risk, onset, and progression. Keine et al. explored the efficacy of a multidomain therapy approach based on the disease risk factor status specific to individuals with AD diagnosis or concern. Their findings indicate previously unidentified connectivity between AD risk factors, suggesting that treatment regimens should be tailored to the individual, and should be multi-modal to simultaneously return risk factors to a normative state. If successfully performed, the possibility to slow progression of AD and even reverse aspects of cognitive decline may become achievable.

Keine et al. completed analysis for forty subjects with subjective cognitive decline (SCD) and mild cognitive impairment (MCI), using novel software from uMETHOD Health. The software is designed to execute a precision-medicine-based approach to develop personalized treatment recommendations, with the goal of slowing or reversing biologic drivers of AD. AD-associated inputs encompassed genomic data, biospecimen measurements, imaging data (such as MRIs or PET scans), medical histories, medications, allergies, comorbidities, relevant lifestyle factors, and results of neuropsychology testing. Algorithms were employed to prioritize physiologic and lifestyle states with the highest probability of contributing to disease status, and these priorities were incorporated into a personalized care plan, which was delivered to physicians and supported by health coaches to increase adherence. With an average of 8.4 months on their treatment plans (equal to about 2.8 iterations of care plans), 80% of individuals in the study showed overall improved memory function scores or held steady, as measured by cognitive evaluations.

It is increasingly recognized that early intervention is key to developing an effective therapy for AD; a precision-medicine platform enables an actionable multidomain therapy for those in the early stages of the disease. Many of the underlying pathologic drivers of the disease (e.g., high homocysteine, genetic biases, insulin resistance, poor diet, poor sleep, lack of exercise, chronic inflammation, toxicity) are modifiable, allowing persons to reduce their risk and potentially delay disease onset. With a multitude of underlying drivers of AD, genetic factors, comorbidities, medications, and optimizations for each person, the amount of data used in generating a care plan quickly accumulates, making a timely process beyond the scope of what a physician can do by hand, and do well quickly. But where manual methods fail, clinical informatics platforms excel. These platforms can provide a personalized treatment method for each individual in a repeatable, predictable, and timely manner. Applying these complex treatment plans to a broader audience through the development of other disease state-specific algorithms could increase the quality of life for many in the aging population.
-end-
Access the article here: http://www.eurekaselect.com/166449

Media Contact:

Helen Bertelli
helen@benecomms.io">helen@benecomms.io

Reference: Keine, Dorothy, et al. Development, application, and results from a precision-medicine platform that personalizes multi-modal treatment plans for mild Alzheimer's disease and at-risk individuals. Current Aging Science, 2018, DOI: 10.2174/1874609811666181019101430

Bentham Science Publishers

Related Cognitive Decline Articles:

Not finding new goals post-retirement associated with greater cognitive decline
Certain middle-aged and older adults, especially women who tend to disengage from difficult tasks and goals after they retire, may be at greater risk of cognitive decline as they age, according to research published by the American Psychological Association.
Hypertension in young adulthood associated with cognitive decline in middle age
Research from Tel Aviv University indicates that high blood pressure in young adulthood is associated with cognitive decline and gait impairment in middle age.
Hearing aids may delay cognitive decline, research finds
Wearing hearing aids may delay cognitive decline in older adults and improve brain function, according to promising new research.
Widowhood accelerates cognitive decline among those at risk for Alzheimer's disease
A new study finds that widowhood can have another profound effect: It may accelerate cognitive decline.
Walnuts may slow cognitive decline in at-risk elderly
Eating walnuts may help slow cognitive decline in at-risk groups of the elderly population, according to a study conducted by researchers in California and Spain.
Research shows that early retirement can accelerate cognitive decline
Early retirement can accelerate cognitive decline among the elderly, according to research conducted by faculty at Binghamton University, State University of New York.
Looking at the way we walk can help predict cognitive decline
The way people walk is an indicator of how much their brains, as well as their bodies, are aging.
High blood pressure treatment may slow cognitive decline
Among middle-aged and older adults, high blood pressure accelerated cognitive decline and treatment slowed the regression.
Depression symptoms in Alzheimer's could be signs for cognitive decline
Depression symptoms in cognitively healthy older individuals together with brain amyloid, a biological marker of Alzheimer's could trigger changes in memory and thinking over time.
Cognitive decline may accelerate after heart attack, angina
Adults with incident coronary heart disease (CHD) are at higher risk for faster cognitive decline in the long-term, according to a study published today in the Journal of the American College of Cardiology.
More Cognitive Decline News and Cognitive Decline Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.